NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

And if it is soft lock, then that begs the question as to whether they will work right through to a topline announcement, on the basis of that soft lock.
For me, it depends what's missing.

If it's only IDH status for a few patients I don't think it really matters.
IDH status has no material bearing on the endpoint data analysis. It's really only an addendum, imo.

But if it's anything else, such as all the data for maybe 10 patients, then soft lock doesn't really take us forward.
You can't (or shouldn't) PR topline data if you are missing critical PFS and OS data for a few patients.

You would just be inviting criticism from the well known critics.